PDE4B Inhibitors Using Regulatory Sequence Recognition to Reduce Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PDE4 inhibitors exhibit significant side effects such as nausea and vomiting due to their lack of subtype selectivity, limiting their clinical application in treating diseases like COPD and cancers.
Innovation Solution
Development of selective PDE4B inhibitors that target the regulatory sequence of PDE4B, utilizing amino acid differences between PDE4B and PDE4D to achieve subtype selectivity, thereby reducing side effects while maintaining inhibitory activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective PDE4 inhibitors are used to treat respiratory and neurological diseases, then therapeutic efficacy is achieved through cAMP signaling enhancement, but serious side effects such as nausea and vomiting occur due to lack of subtype selectivity
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular structures (formula I compounds) that target only the PDE4B subtype through interactions with the regulatory sequence and catalytic domain, while leaving other PDE4 subtypes (PDE4A, 4C, 4D) unaffected. This selective targeting maintains therapeutic efficacy for PDE4B-mediated conditions while avoiding the side effects caused by non-selective inhibition of other subtypes.
Solution Approach 2:
The patent utilizes parameter changes by exploiting the amino acid sequence differences between PDE4B and other PDE4 subtypes, particularly at positions 674 (Leu in PDE4B vs. Gln in PDE4D) in the regulatory sequence. The inhibitor molecules are designed to recognize and bind specifically to these sequence variations, achieving subtype selectivity through changes in molecular recognition parameters.
2Reliability
If PDE4 inhibitors target the catalytic domain to achieve inhibition, then inhibitory activity is obtained, but subtype selectivity is lost because the catalytic domains of all PDE4 subtypes are highly homologous
Solution Approach 1:
The patent segments the PDE4 inhibitor binding site into two functional regions: the catalytic domain (for inhibitory activity) and the regulatory sequence (for subtype selectivity). By targeting both regions, the inhibitor achieves dual functionality - maintaining strong inhibitory activity while gaining subtype specificity through interactions with the regulatory sequence that differs between subtypes.
Solution Approach 2:
The regulatory sequence acts as an intermediary element that mediates between the catalytic domain and the inhibitor molecule. It provides the selective binding interface that distinguishes PDE4B from other subtypes, while the catalytic domain provides the inhibitory function. This intermediary role of the regulatory sequence enables subtype-selective inhibition.
Data Source
AI summary
A compound represented by formula I, stereoisomers or pharmaceutically acceptable salts thereof, or a pharmaceutical composition containing same, and the use thereof as a PDE4B inhibitor in the preparation of a drug for treatment of related diseases. Each group in formula (I) is as defined in the description.